av电影免费-国产精品综合-久久免费精品-一区二区三区国产-久久久国产一区-av一级在线

技術(shù)文章您現(xiàn)在的位置:首頁 > 技術(shù)文章 > Clodronate Liposomes氯膦酸鹽脂質(zhì)體助力前列腺癌骨轉(zhuǎn)移模型巨噬細(xì)胞研究

Clodronate Liposomes氯膦酸鹽脂質(zhì)體助力前列腺癌骨轉(zhuǎn)移模型巨噬細(xì)胞研究

更新時(shí)間:2024-12-14   點(diǎn)擊次數(shù):596次

中文摘要:

轉(zhuǎn)移性去勢抵抗性前列腺癌 (PC) 是 PC 的最后階段,對雄激素剝奪療法 (ADT) 產(chǎn)生耐藥性。盡管對疾病機(jī)制的理解取得了進(jìn)展,但轉(zhuǎn)移性微環(huán)境對 ADT 耐藥的具體貢獻(xiàn)在很大程度上仍然未知。目前的研究確定,巨噬細(xì)胞是患者骨轉(zhuǎn)移性 PC 的主要微環(huán)境成分。使用一種新的體內(nèi)模型,我們證明巨噬細(xì)胞通過誘導(dǎo) ECM 受體基因表達(dá)的傷口愈合樣反應(yīng)對恩雜魯胺耐藥至關(guān)重要。從機(jī)制上講,巨噬細(xì)胞通過細(xì)胞因子激活素 A 驅(qū)動(dòng)耐藥性,從而在 PC 細(xì)胞中誘導(dǎo)纖連蛋白 (FN1)-整合素 α 5 (ITGA5)-酪氨酸激酶 Src (SRC) 信號級聯(lián)反應(yīng)。這種新機(jī)制得到了患者轉(zhuǎn)錄組學(xué)數(shù)據(jù)集的生物信息學(xué)分析的強(qiáng)烈支持。此外,使用新型特異性抑制劑的巨噬細(xì)胞耗竭或 SRC 抑制顯著抑制了耐藥生長。總之,我們的研究結(jié)果闡明了巨噬細(xì)胞誘導(dǎo)的轉(zhuǎn)移性 PC 抗雄激素耐藥的新機(jī)制,以及治療這種致命疾病的有前途的治療方法。

英文摘要:

Metastatic castration-resistant prostate cancer (PC) is the final stage of PC that acquires resistance to androgen deprivation therapies (ADT). Despite progresses in understanding of disease mechanisms, the specific contribution of the metastatic microenvironment to ADT resistance remains largely unknown. The current study identified that the macrophage is the major microenvironmental component of bone-metastatic PC in patients. Using a novel in vivo model, we demonstrated that macrophages were critical for enzalutamide resistance through induction of a wound-healing–like response of ECM–receptor gene expression. Mechanistically, macrophages drove resistance through cytokine activin A that induced fibronectin (FN1)-integrin alpha 5 (ITGA5)–tyrosine kinase Src (SRC) signaling cascade in PC cells. This novel mechanism was strongly supported by bioinformatics analysis of patient transcriptomics datasets. Furthermore, macrophage depletion or SRC inhibition using a novel specific inhibitor significantly inhibited resistant growth. Together, our findings elucidated a novel mechanism of macrophage-induced anti-androgen resistance of metastatic PC and a promising therapeutic approach to treat this deadly disease.


論文信息:

論文題目: Macrophages promote anti-androgen resistance in prostate cancer bone disease

期刊名稱:JEM- J Exp Med

時(shí)間期卷:J Exp Med (2023) 220 (4): e20221007.

在線時(shí)間:2022年2月7日

DOI:doi.org/10.1084/jem.20221007


Clodronate Liposomes氯膦酸鹽脂質(zhì)體助力前列腺癌骨轉(zhuǎn)移模型巨噬細(xì)胞研究,Liposoma巨噬細(xì)胞清除劑Clodronate Liposomes見刊于JEM:

image.png


Liposoma巨噬細(xì)胞清除劑Clodronate Liposomes氯膦酸二鈉脂質(zhì)體的材料和方法

image.png

JEM期刊巨噬細(xì)胞清除解決方案 

Drug treatments

Vehicle and enzalutamide (30 mg/kg body weight), SRC inhibitor eCF506 (20 mg/kg body weight) was given via daily oral gavage; L-Clod/PBS (1 mg/mouse, twice a week) were administered by i.v. injection; DT or control Glu52-DT (25 μg/kg body weight, every other day), anti-Ly-6G depleting Abs (200 μg/mouse, every other day), activin-A receptor inhibitor SB-505124 (5 mg/kg body weight, every other day) were delivered by i.p. injection. In some experiments, mice continuously received doxycycline diet (625 mg/kg). Enzalutamide was synthesized by chemical core at Memorial Sloan Kettering Cancer Center; eCF506 was kindly provided by A. Unciti-Broceta; L-Clod/PBS was from Liposoma; anti-Ly-6G Abs (clone #1A8) were from BioxCell; activin-A receptor inhibitor SB-505124 was from Selleckchem; and DT/Glu52-DT was from Sigma-Aldrich.

靶點(diǎn)科技(北京)有限公司

靶點(diǎn)科技(北京)有限公司

地址:中關(guān)村生命科學(xué)園北清創(chuàng)意園2-4樓2層

© 2025 版權(quán)所有:靶點(diǎn)科技(北京)有限公司  備案號:京ICP備18027329號-2  總訪問量:332453  站點(diǎn)地圖  技術(shù)支持:化工儀器網(wǎng)  管理登陸

主站蜘蛛池模板: 日韩亚洲欧美理论片 | 成年人在线观看视频免费 | 另类二区三四 | 99在线视频精品 | 亚洲网址在线观看 | 91精品国产薄丝高跟在线看 | 一级a毛片免费 | 亚洲欧美日韩精品久久久 | 亚洲的天堂| 亚洲精品日韩中文字幕久久久 | 在线成人播放毛片 | 99国产精品高清一区二区二区 | hd欧美xxx欧美极品hd | 久久污| 久久91av| 欧美成人www在线观看网页 | 国产手机精品一区二区 | 亚洲性爰视频 | 国产精品久久亚洲一区二区 | 高清午夜线观看免费 | 日韩在线三级 | 美国一级毛片片aaa 美国一级毛片片aa成人 | 尹人香蕉久久99天天拍 | 亚洲视频在线观 | 九九视频只有精品六 | 久久久久久久国产视频 | 99国产精品农村一级毛片 | 精品久久久久不卡无毒 | 欧美一区二区三区久久综 | 国产毛片久久精品 | 毛片免费观看成人 | 久久成年人 | 99热r| 一级视频在线观看 | 青青草福利视频 | 女人张开腿男人捅 | a国产精品 | 2021国产成人精品久久 | www.日本三级| 成人欧美一区二区三区在线 | 亚洲品质自拍网站 |